Wall Street’s reaction to phase I news in chondrosarcoma from Inhibrx Inc. puzzled some onlookers and brought renewed attention to the rare disease, which is also the most common form of primary bone cancer in adults. Big pharma and smaller concerns have been throwing drug prospects at the condition for years without much luck.